BerGenBio ASA BRRGF
At closeFeb 25, 2026, 4:00 PM EST
- YTD
- +0.00%
- 1 year
- +0.00%
- Market cap
- 9.49B
- Profit margin
- -877.36%
- EPS (ttm)
- -204.13
- P/E ratio
- -0.81
- YTD return
- +0.00%
- 1-year return
- +0.00%
- Volume
- 37.30K
- Avg volume
- 3.95K
- Open
- 0.97094
- Previous close
- 97.09
- Day's range
- 0.025 – 97.09
- 52-week range
- 0.025 – 97.09
- Beta
- 1.31
- Earnings date
- May 19, 2026
Key statistics
- Enterprise value
- 198.90M
- PEG ratio
- 0.00
- Price / sales
- 15.56
- Price / book
- 3.77
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -150.82%
Next earnings
May 19, 2026
Expected May 19, 2026. Consensus EPS estimate -80.32.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 19, 2026 | Mar 30, 2026 | -80.32 | — | — | — |
| Feb 19, 2026 | Dec 30, 2025 | -69.29 | — | — | — |
| Nov 19, 2025 | Sep 30, 2025 | -0.55311 | — | — | — |
| Aug 20, 2025 | Jun 30, 2025 | — | -0.06836 | — | — |
| May 21, 2025 | Mar 31, 2025 | — | -0.06412 | — | — |
| Feb 26, 2025 | Dec 31, 2024 | -6.13 | -6.13 | 0.00 | 0.00% |
About BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapies for challenging conditions. This includes cancers that are immune-evasive, drug-resistant, or metastatic, as well as various respiratory diseases. Its leading drug candidate, Bemcentinib, is an orally available, small molecule AXL inhibitor that has progressed to Phase II clinical development. This involves studies across several significant cancer indications and for COVID-19. Specifically, its Phase II trials are focused on treating non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Another promising compound in its pipeline is tilvestamab, an anti-AXL antibody currently undergoing Phase Ib clinical evaluation. The company maintains a collaborative agreement with Merck & Co. concerning its clinical trial initiatives. Founded in 2007, BerGenBio ASA is headquartered in Bergen, Norway.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- NO
- Employees
- 13
- Website
- bergenbio.com
News
Your note
Sign in to keep a note on BRRGF — it syncs with the Stock Master app.